Report post

Who owns Denali Therapeutics Inc?

Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA. DNLI | Complete Denali Therapeutics Inc. stock news by MarketWatch.

Will Denali Therapeutics offer a 30-day option?

In addition, Denali Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered. The proposed offering is subject to market and other conditions, and there can be no assuran

What is Denali Therapeutics' underwritten public offering?

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering.

The World's Leading Crypto Trading Platform

Get my welcome gifts